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Background: Chronic obstructive pulmonary disease (COPD) is influenced by both environmental and genetic
factors. Few gene studies of the Chinese population have focused on COPD. We investigated candidate genes
associated with susceptibility to COPD in the Chinese Han population.
Methods: A total of 331 COPD patients and 213 control subjects were recruited for this study. Nighty-seven
single-nucleotide polymorphisms (SNPs) of 46 genes were selected for genotyping. Genotypes were determined
using multiplex polymerase chain reaction (PCR).
Results: Significant differences between patients and healthy controls were observed in the allele frequencies of
seven SNPs: rs1205 C, rs2353397 C, rs20541 T, rs2070600 G, rs10947233 G, rs1800629 G, and rs2241712 A. After
Bonferroni correction, rs2353397 C was most strongly associated with susceptibility to COPD. Haplotype analysis
showed that the frequencies of the GC, GT haplotypes of rs2241718 (TGF-β1 gene), and rs6957 (CDC97 gene) were
significantly higher in the control group than in the COPD case group (p=1.88×10-9); the frequencies of the TT
haplotype of rs1205 and rs2808630 (CRP gene) were significantly higher in the control group (p=0.0377).
Conclusion: Our study suggests some genetic variants associated with the susceptibility of COPD in the Chinese
Han population.
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Chronic obstructive pulmonary disease (COPD) is charac-
terized by progressive airflow limitation driven by an ab-
normal inflammatory response of the airways to inhaled
particles and fumes [1]. The disease is predicted to be-
come the third most common cause of death and the
fifth most common cause of disability in the world by
2020 [2]. This disease remains under-recognized and
under-diagnosed; the pathogenesis needs to be investigated.
Cigarette smoking is one of the most important risk
factors for COPD, but the severity of the disease varies
considerably, irrespective of the number of pack-years of
smoking. Furthermore, only a minority of smokers (20%)* Correspondence: wanhuanying@hotmail.com
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reproduction in any medium, provided the ordevelop the disease clinically, suggesting that in addition
to smoking, COPD is partially genetically determined
[3,4]. COPD may be caused by a combination of genes
and environmental influences. Genes have been asso-
ciated with COPD in a family-based study, and some
previous studies have demonstrated familial aggregation
of COPD. The heritability of COPD is estimated to be
40–77% [5]. Some other twin studies have also indicated
a genetic contribution to clinically relevant parameters
of pulmonary function, such as forced expiratory volume
in 1s (FEV1) and forced vital capacity (FVC) [6,7].
Many studies of candidate genes for COPD and pul-
monary function have been conducted over the past few
years. Above all, genome-wide association studies
(GWASs) have identified some loci associated with sus-
ceptibility to COPD [8-12] but with varying degrees of
reproducibility. Conflicting results among these studies. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Gene location and alleles of 97 single-nucleotide polymorphisms (SNPs)
SNP_ID Gene Chrom-osome Alleles SNP_ID Gene Chrom-osome Alleles
rs1800610 [1] TNF-α 6 C/T rs673400 [14] SERPINA2 2 C/G
rs1799964 [1] TNF-α 6 C/T rs7583463 [15] SERPINA2 2 A/C
rs361525 [2] TNF-α 6 A/G rs2736100 [8] TERT 5 G/T
rs1800629 [3] TNF-α 6 A/G rs10069690 [8] TERT 5 C/T
rs2808630 [4] CRP 1 C/T rs34829399 [8] TERT 5 C/T
rs1205 [5] CRP 1 C/T rs4246742 [8] TERT 5 A/T
rs1130864 [4] CRP 1 C/T rs2736118 [8] TERT 5 A/G
rs1059823 [6] SLC11A1 2 A/G rs2736122 [8] TERT 5 C/T
rs1130866 [7] SFTPB 2 C/T rs2853677 [8] TERT 5 C/T
rs2353397 [8] HHIP 4 C/T rs2853676 [8] TERT 5 A/G
rs13147758 [8] HHIP 4 A/G rs1881457 [16] IL-13 5 A/C
rs2035901 [8] HHIP 4 A/G rs1295685 [16] IL-13 5 C/T
rs6537302 [8] HHIP 4 A/T rs1800925 [16] IL-13 5 C/T
rs1032295 [8] HHIP 4 T/G rs2066960 [16] IL-13 5 A/C
rs12504628 [8] HHIP 4 C/T rs20541 [16] IL-13 5 C/T
rs17019336 [8] HHIP 4 A/T rs16909898 [8] PTCH1 9 A/G
rs3749893 [8] TSPYL-4 6 A/G rs10512249 [8] PTCH1 9 C/T
rs4987835 [9] Bcl-2 18 A/G rs35621 [17] ABCC1 16 C/T
rs2292566 [10] EPHX1 1 A/G rs2241718 [18] TGF-β1 19 C/T
rs1051740 [11] EPHX1 1 C/T rs56155294 [18] TGF-β1 19 C/T
rs868966 [11] EPHX1 1 A/G rs1800469 [18] TGF-β1 19 C/T
rs25882 [12] CSF2 5 C/T rs2241712 [18] TGF-β1 19 A/G
rs829259 [13] PDE4D 5 A/T rs2277027 [8] ADAM19 5 A/C
rs6712954 [14] SERPINA2 2 A/G rs2280090 [19] ADAM33 20 A/G
rs2280091 [19] ADAM33 20 A/G rs4073 [12] IL-8 4 A/T
rs1435867 [8] PID1 2 C/T rs8192288 [30] SOD3 4 G/T
rs10498230 [8] PID1 2 C/T rs2571445 [20] TNS1 2 C/T
rs3995090 [20] HTR4 5 A/C rs1003349 [31] MMP14 14 G/T
rs6889822 [8] HTR4 5 A/G rs737693 [32] MMP12 11 A/T
rs1531697 [9] Bcl-2 18 A/T rs2276109 [32] MMP12 11 A/G
rs1042713 [21] ARDB2 5 A/G rs1052443 [8] NT5DC1 6 A/C
rs3024791 [22] SFTPB 2 A/G rs10947233 [8] PPT2 6 G/T
rs511898 [23] ADAM33 20 C/T rs1051730 [33] CHRNA3 15 C/T
rs2853209 [23] ADAM33 20 A/T rs11106030 [20] DCN 12 A/C
rs6555465 [8] ADCY2 5 A/G rs584367 [34] sPLA2s 1 C/T
rs10075508 [13] PDE4D 5 C/T rs9904270 [26] CDC6 17 C/T
rs12899618 [20] THSD4 15 A/G rs2395730 [8] DAAM2 6 A/C
rs3091244 [8] SFXN1 5 A/C/T rs3817928 [8] GPR126 6 A/G
rs8004738 [24] SERPINA1 14 A/G rs11155242 [8] GRP126 6 A/C
rs709932 [24] SERPINA1 14 A/G rs7776375 [8] GPR126 6 A/G
rs4934 [25] SERPINA3 14 A/G rs6937121 [8] GPR126 6 G/T
rs13706 [26] CDC6 17 A/G rs1042714 [35] ARDB2 5 C/G
rs7217852 [26] CDC6 17 A/G rs1800796 [36] IL-6 7 C/G
rs2077464 [26] CDC6 17 A/G rs2236307 [31] MMP14 14 C/T
rs2070600 [20] AGER 6 A/G rs2236302 [31] MMP14 14 C/G
rs6957 [27] CDC97 19 A/G rs2230054 [37] IL-8RB 2 C/T
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rs1042522 [28] P53 17 C/G rs1422795 [8] ADAM19 5 A/G
rs1695 [29] GSTP1 11 A/G rs6830970 [8] FAM13A 4 A/G
rs2869967 [8] FAM13A 4 C/T
References listed in supplemental document.
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sizes. In the past, candidate gene studies have focused
on a single gene or on a few genes in combination; these
genes were identified based on prior knowledge or sus-
pected mechanisms of disease pathogenesis. Nonethe-
less, elucidating the genetics of respiratory disorders is
severely hampered by genetic heterogeneity, the low
penetrance of individual disease alleles, and the potential
for gene–gene and gene–environment interactions. To
date, the only proven genetic risk factor for COPD is the
severe deficiency of alpha-1-antitrypsin (AAT), which is
associated with a predisposition to early onset panacinar
(panlobular) emphysema [13].
Furthermore, few gene studies performed on the Chinese
population have focused on COPD. However, in China,
the disease is increasingly prevalent. A 2007 survey of
20,245 participants in seven regions of China reported
the occurrence of COPD in adults aged ≥40 years to be
8.2% [14]. Therefore, more gene-association studies are
needed to identify genetic polymorphisms associated
with the development of COPD in the Chinese
population.
The aim of our current case–control study was to lo-
cate genes related to susceptibility to COPD in the
Chinese Han population. We aimed to identify loci
associated with COPD among 97 single-nucleotide
polymorphisms (SNPs) of 46 genes (Table 1).
Methods
Subjects
In total, 331 COPD patients were recruited: 256 from the
Department of Respiratory Diseases of Shanghai Rui Jin
Hospital, 60 from the Shanghai Jing-an Geriatric Hospital,
and 15 from the Shanghai Gong Hui Hospital. COPD was
diagnosed according to the criteria established by the
NHLBI/WHO Global Initiative for COPD (GOLD) [15].
The diagnoses were based on certain patient parameters
(e.g., age≥40 years and smoking history of ≥20 pack-years)
and on the presence of relentless and progressive symp-
toms: cough, productive sputum, and breathlessness over
many years; airflow limitation as indicated by FEV1/
FVC≤70%; FEV1 reversibility after the inhalation of salbu-
tamol <12% of the pre-bronchodilator FEV1 (MS-Body
Diffusion, Germany). Patients were excluded if they had a
comorbid diagnosis such as asthma or lung cancer, or had
radiographic abnormalities suggestive of other significant
respiratory diseases and any hereditary diseases.Control subjects (n = 213) were selected from a pool
of healthy people who visited the general health checkup
center of Shanghai Rui Jin Hospital during the same
period. The enrollment criteria for the controls were as
follows: age≥40 years, smoker, no known disease, no his-
tory of any disease. Lung function was measured at base-
line following the American Thoracic Society/European
Respiratory Society standard procedure to confirm no
evidence of airflow obstruction. All of the COPD
patients and control subjects were ethnic Han Chinese.
The study protocol was approved by the medical ethics
committee of Shanghai Rui Jin Hospital, Shanghai Jiaotong
University School of Medicine, and all participants gave
written informed consent.
DNA extraction and genotyping
We chose 97 candidate SNPs identified in previously
published GWASs and by searching the dbSNP database
of NCBI (references in Additional file 1: Table S1). Their
minor allele frequencies (MAFs) were >0.05 in the Han
Chinese population we studied.
A 4-ml peripheral blood sample was obtained from
each participant for DNA analysis. Plasma was separated
by centrifuge and stored at −80°C until further use. We
extracted genomic DNA using a QuickGene DNA whole
blood kit, (Life Sciences, FUJIFILM, Japan). Any sample
with DNA concentration <10 ng/ul was excluded, and
another sample was acquired.
For genotyping, we first performed multiplex PCR, a
variant of PCR that enables simultaneous amplification
of many targets of interest in one reaction by using more
than one pair of primers [16]. Mass-ARRAY™ Assay De-
sign 2.0 software was used to design multiplex primers
for each SNP: 1st PCR primer, 2nd PCR primer, and
UEP primer. The primers of 97 SNPs are shown in
Additional file 1: Table S1. Genotyping was achieved
using the Mass-Array™ Technology platform of Sequenom,
Inc. (San Diego, CA, USA). For quality control, two in-
dependent readers interpreted the results, and a ran-
dom selection of 10% of all samples was retested. No
discrepancies were discovered in the replicate tests. All
genotyping analyses were blinded with respect to the
case/control status, and all samples were analyzed in
the same lab and under the same conditions. The
results were 100% concordant. Several SNP samples
were finally excluded because ≥10% of the genotyping
data were missing.
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Data analyses were performed using the Statistical Pack-
age for the Social Science 20.0 (SPSS, Inc., Chicago, IL,
USA). Continuous variables (age, smoking history, and
pulmonary function) were calculated as means (± stand-
ard deviation). The two-sided Student’s t-test was used
to determine significant differences in clinical data be-
tween the COPD cases and the control subjects. The sig-
nificance level for t tests of clinical information was
0.05. The χ2 test and unconditional logistic method were
applied to compare genotype and allele frequencies be-
tween the two groups, logistic analysis was adjusted for
age, gender and smoking. Frequencies were compared,
respectively, using a p cutoff of 0.05 (like previous stud-
ies) and the Bonferroni correction method for multiple
testing. The relative risk associated was estimated as
an odds ratio (OR) with a 95% confidence interval
(95% CI). Each of the SNPs in the control group was
analyzed for Hardy-Weinberg equilibrium (HWE)
using chi-square test and exact test, SNPs were
excluded from the analysis if they were out of HWE
(p≤0.05). Haplotype frequencies and linkage disequilib-




The study population characteristics are described in
Table 2. They did not significantly differ in sex, age, or
smoking history. FEV1 predictive (FEV1%) and FEV1/
FVC of the case group were significantly decreased com-
pared with the control group (p<0.05).
Association analysis of each genotype
Eight SNPs (rs361525, rs1042713, rs34829399, rs2853677,
rs2571445, rs8192288, rs2066960, and rs2230054) that
deviated from HWE in the controls were removed
from the association analysis. Thirteen SNPs (rs1130866,Table 2 Demographics of COPD patients and control
subjects






FEV1/FVC 54±13.8* 85±7.6* p<0.05
FEV1/predicted(%) 49±18.1# 88±17.0# p<0.05
Data were presented as the means ± SD. FEV1, forced expiratory volume in 1
sec; FVC, forced vital capacity; *p<0.05 significant difference vs control.
#p<0.05 significant difference vs control.rs56155294, rs10498230, rs2035901, rs3091244, rs511898,
rs2869967, rs7583463, rs2276109, rs737693, rs9904270,
rs4934, and rs6830970) were also eliminated from the ana-
lysis due to lack of genotyping data in ≥10% of the sample.
Finally, 76 of the 97 SNPs were included in the association
analysis. The allele frequencies (Table 3) and the genotype
distributions for these SNPs were analyzed in samples
from 331 COPD patients and 213 control subjects. Seven
SNPs tended to be associated with COPD: rs2353397,
rs1800629, rs2241712, rs1205, rs20541, rs2070600, and
rs10947233. Among these seven SNPs, after Bonferroni
correction, rs2353397 was most strongly associated with
susceptibility to COPD. The C allele (rs2353397) of the
human hedgehog interacting protein (HHIP) gene occurred
more frequently in COPD patients (58%) than in the
control subjects (29%) (OR = 2.16, 95% CI 1.66–2.81,
p<0.0001, p(Bonferroni) <0.0001). The G allele (rs1800629)
of the TNF-α gene was more frequently detected in COPD
patients (95%) versus control subjects (90%) (OR=1.97,
95% CI 1.21–3.21, p=0.0060, p(Bonferroni)=0.4560). The
frequency of the A allele (rs2241712) of the TGF-β1 gene
was significantly higher in COPD patients (52%) than in
healthy controls (45%) (OR=1.24, 95% CI 0.96–1.59,
p=0.0460, p(Bonferroni)=3.7848). The C allele (rs1205) of
the CRP gene occurred more frequently in COPD patients
(47%) compared with control subjects (40%) (OR=1.48,
95% CI 1.14–1.91, p=0.0030, p(Bonferroni)=0.2280). More
COPD patients (35%) carried the T allele (rs20541) of
the IL-13 gene than control subjects (28%) (OR=1.36,
95% CI 1.04–1.80, p=0.0280, p(Bonferroni)=2.1280).
The G allele (rs2070600) of the AGER gene was found
more frequently in COPD patients (81%) than in
healthy controls (73%) (OR=1.47, 95% CI 1.08–1.98,
p=0.0130, p(Bonferroni)=0.9880). The G allele (rs10947233)
of the PPT2 gene occurred more frequently in COPD
patients (79%) than in control subjects (72%) (OR=1.51,
95% CI 1.12–2.03, p=0.0060, p(Bonferroni)=0.4560).
For analysis of genotypic association of these seven
SNPs under certain genotype models (Table 4), rs2353397
TT protected subjects from the disease; CC, CT carriers
were more susceptible to COPD (OR=1.01, 95% CI 0.79–
1.32, p<0.0001). The rs1800629 GG homozygous carriers
exhibited an increased susceptibility to the disease com-
pared with AA, GA carriers (OR=1.90, 95% CI 1.12–3.21,
p=0.0170). The rs1205 CC, CT genotype increased risk
for COPD compared with the TT homozygous geno-
type (OR=1.82, 95% CI 1.21–2.73, p=0.0040). Indivi-
duals carrying the rs20541 TT, CT genotype were at a
significantly higher risk for COPD than were healthy
subjects carrying the CC genotype (OR=1.47, 95% CI
1.01–2.13, p=0.0450). The rs2070600 GG homozygous
carriers tended to develop COPD more frequently that
AA, GA carriers (OR=1.55, 95% CI 1.06–2.26, p=0.0240).
rs10947233 GG, GT carriers were associated with













rs1059823 G 139(33) 222(34) 0.0181 0.8929 1.01 0.79-1.32 67.8604 0.8290 0.97 0.74-1.27 63.0040
A 283(67) 440(66)
rs1205 C 168(40) 308(47) 5.2168 0.0223 1.34 1.04-1.71 1.6948 0.0030 1.48 1.14-1.91 0.2280
T 252(60) 346(53)
rs17019336 A 136(32) 242(37) 2.1770 0.1401 1.21 0.94-1.57 10.6476 0.0670 1.28 0.98-1.68 5.0920
T 284(68) 416(63)
rs1799964 T 333(79) 519(79) 0.0008 0.9772 1.00 0.74-1.36 74.2672 0.8140 0.96 0.71-1.31 61.8640
C 87(21) 135(21)
rs1800610 T 71(17) 112(17) 0.0117 0.9137 1.02 0.74-1.41 69.4412 0.9007 0.98 0.70-1.38 68.4532
C 355(83) 550(83)
rs2077464 T 271(65) 420(66) 0.1909 0.6621 1.06 0.82-1.37 50.3196 0.8230 1.03 0.79-1.35 62.5480
C 149(35) 218(34)
rs2236302 C 369(88) 584(89) 0.2011 0.6539 1.09 0.75-1.59 49.6964 0.4140 1.18 0.80-1.75 31.4640
G 51(12) 74(11)
rs2292566 A 125(30) 209(32) 0.4800 0.4884 1.10 0.84-1.43 37.1184 0.7630 1.04 0.79-1.38 57.9880
G 295(70) 449(68)
rs2353397 C 123(29) 382(58) 83.3798 6.8×10-20 3.29 2.54-4.28 5.2×10-18 <0.0001 2.16 1.66-2.81 <0.0001
T 297(71) 280(42)
rs25882 T 147(35) 240(36) 0.2421 0.6227 1.07 0.83-1.38 47.3252 0.4650 1.10 0.85-1.44 35.3400
C 273(65) 418(64)
rs2808630 C 66(16) 119(18) 1.0136 0.3140 1.18 0.85-1.65 23.8640 0.2120 0.86 0.69-1.09 16.1120
T 354(84) 539(82)
rs3749893 A 286(67) 454(69) 0.6232 0.4299 1.11 0.86-1.44 32.6724 0.4510 1.11 0.84-1.46 34.2760
G 140(33) 200(31)
rs4987835 A 236(56) 382(60) 1.7185 0.1899 1.19 0.92-1.51 14.4324 0.2950 1.15 0.88-1.49 22.4200
G 184(44) 252(40)
rs709932 A 73(17) 131(20) 1.2714 0.2595 1.20 0.87-1.65 19.7220 0.2860 1.19 0.86-1.65 21.7360
G 347(83) 519(80)
rs7217852 A 273(65) 434(66) 0.0652 0.7985 1.03 0.80-1.34 60.6860 0.8460 1.03 0.79-1.34 64.2960
G 147(35) 226(34)
rs7776375 A 270(63) 438(66) 0.8832 0.3473 1.13 0.88-1.46 26.3948 0.2570 1.17 0.89-1.52 19.5320
G 156(37) 224(34)
rs10069690 C 331(80) 520(81) 0.0264 0.8709 1.03 0.75-1.40 66.1884 0.6480 1.08 0.78-1.48 49.2480
T 81(20) 124(19)
rs1051740 T 247(60) 403(61) 0.0424 0.8369 1.03 0.79-1.32 63.6044 0.8910 1.02 0.79-1.32 67.7160
C 163(40) 259(39)
rs11155242 A 372(90) 604(91) 0.5784 0.4469 1.18 0.77-1.79 33.9644 0.2560 1.28 0.83-1.94 19.4560
C 42(10) 58(9)
rs1295685 T 118(29) 221(33) 2.8124 0.0935 1.26 0.96-1.64 7.1060 0.1730 1.21 0.92-1.60 13.1480
C 296(71) 441(67)
rs1435867 C 55(13) 90(14) 0.0200 0.8877 1.03 0.72-1.47 67.4652 0.5300 0.89 0.62-1.29 40.5080
T 355(87) 566(86)
rs16909898 G 33(8) 54(8) 0.0101 0.9200 1.02 0.65-1.61 69.9200 0.3140 0.79 0.50-1.25 23.8640
A 379(92) 606(92)
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rs1881457 A 308(74) 495(75) 0.0726 0.7876 1.04 0.78-1.38 59.8576 0.9120 1.02 0.76-1.36 69.3120
C 108(26) 167(25)
rs2241718 T 114(28) 206(31) 1.4433 0.2296 1.18 0.90-1.55 17.4496 0.2930 1.16 0.88-1.53 22.2680
C 298(72) 456(69)
rs2277027 C 64(15) 106(16) 0.0586 0.8088 1.04 0.74-1.46 61.4688 0.8350 0.96 0.68-1.36 63.4600
A 350(85) 556(84)
rs2736100 T 231(57) 368(58) 0.1539 0.6948 1.05 0.82-1.35 52.8048 0.6340 1.06 0.82-1.38 48.1840
G 173(43) 262(42)
rs35621 C 305(74) 499(75) 0.1317 0.7167 1.05 0.79-1.40 54.4692 0.3480 1.15 0.86-1.54 26.4480
T 105(26) 163(25)
rs3995090 C 288(70) 461(71) 0.1521 0.6965 1.06 0.80-1.39 52.9340 0.4200 1.12 0.84-1.48 31.9200
A 122(30) 185(29)
rs4246742 A 244(60) 429(65) 3.0339 0.0815 1.25 0.97-1.61 6.1940 0.0510 1.32 1.01-1.71 3.8760
T 166(40) 233(35)
rs6712954 G 321(78) 545(82) 3.1679 0.0751 1.32 0.97-1.79 5.7076 0.0560 1.38 1.01-1.89 4.2560
A 91(22) 117(18)
rs829259 A 137(33) 233(35) 0.4250 0.5145 1.09 0.84-1.41 39.1020 0.9300 1.01 0.77-1.32 70.6800
T 275(67) 429(65)
rs10075508 T 69(16) 108(17) 0.0253 0.8736 1.03 0.74-1.43 66.3936 0.9070 1.02 0.72-1.44 68.9320
C 357(84) 544(83)
rs10512249 T 33(8) 52(8) 0.0606 0.8056 1.06 0.67-1.67 61.2256 0.4950 1.16 0.75-1.80 37.6200
C 383(92) 570(92)
rs12899618 G 370(89) 579(89) 0.0806 0.7765 1.06 0.72-1.56 59.0140 0.6010 1.11 0.75-1.65 45.6760
A 48(11) 71(11)
rs13706 G 272(65) 427(65) 0.0598 0.8068 1.03 0.80-1.34 61.3168 0.8300 0.97 0.75-1.27 63.0800
A 148(35) 225(35)
rs1531697 A 255(61) 411(63) 0.5370 0.4637 1.10 0.85-1.41 35.2412 0.4750 1.10 0.85-1.43 36.1000
T 163(39) 239(37)
rs1800925 T 62(15) 105(17) 0.8620 0.3531 1.18 0.84-1.66 26.8356 0.1000 1.32 0.94-1.85 7.6000
C 352(85) 507(83)
rs3024791 G 388(93) 616(95) 1.5299 0.2161 1.39 0.82-2.34 16.4236 0.3820 1.25 0.76-2.06 29.0320
A 28(7) 32(5)
rs6537302 A 310(75) 480(77) 0.7206 0.3959 1.13 0.85-1.51 30.0884 0.9110 1.10 0.76-1.36 69.2360
T 104(25) 142(23)
rs6555465 G 195(46) 310(48) 0.4399 0.5072 1.09 0.85-1.39 38.5472 0.5010 1.09 0.85-1.41 38.0760
A 231(54) 338(52)
rs673400 C 178(43) 278(43) 0.0062 0.9371 1.01 0.79-1.30 71.2196 0.9280 0.99 0.76-1.28 70.5280
G 238(57) 368(57)
rs6889822 G 268(64) 417(65) 0.0594 0.8073 1.03 0.80-1.34 61.3548 0.5000 1.10 0.84-1.43 38.0000
A 148(36) 223(35)
rs8004738 G 184(44) 275(44) 0.0092 0.9236 1.01 0.79-1.30 70.1936 0.6650 1.01 0.82-1.37 50.5400
A 232(56) 351(56)
rs1003349 G 238(57) 392(60) 0.8897 0.3456 1.13 0.88-1.45 26.2656 0.2340 1.17 0.90-1.51 17.7840
T 178(43) 260(40)
rs1032295 T 320(75) 523(80) 3.1870 0.0742 1.30 0.97-1.74 5.6392 0.1130 1.28 0.94-1.73 8.5880
G 106(25) 133(20)
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Table 3 Allele frequencies in COPD and control subjects for SNPs (Continued)
rs1042522 C 184(44) 304(47) 0.8170 0.3660 1.12 0.88-1.43 27.8160 0.4090 1.11 0.86-1.44 31.0840
G 236(56) 348(53)
rs1052443 C 281(67) 457(71) 1.7602 0.1846 1.20 0.92-1.56 14.0296 0.1610 1.22 0.93-1.60 12.2360
A 139(33) 189(29)
rs12504628 T 305(72) 475(72) 0.0847 0.7710 1.04 0.79-1.37 58.5960 0.9810 1.04 0.76-1.33 74.5560
C 121(28) 181(28)
rs1695 G 72(17) 126(19) 0.6673 0.4140 1.14 0.83-1.57 31.4640 0.4650 1.13 0.82-1.57 35.3400
A 346(83) 530(81)
rs1800469 C 182(44) 315(48) 2.1252 0.1449 1.20 0.94-1.54 11.0124 0.2010 1.74 1.35-2.27 15.2760
T 234(56) 337(52)
rs20541 T 118(28) 228(35) 5.3633 0.0206 1.37 1.05-1.79 1.5656 0.0280 1.36 1.04-1.80 2.1280
C 302(72) 426(65)
rs2070600 G 312(73) 529(81) 8.1712 0.0043 1.52 1.14-2.03 0.3268 0.0130 1.47 1.08-1.98 0.9880
A 114(27) 127(19)
rs2853209 A 191(45) 305(47) 0.1953 0.6586 1.06 0.83-1.35 50.0536 0.9890 0.10 0.77-1.29 75.1640
T 231(55) 349(53)
rs4073 A 185(44) 300(46) 0.5198 0.4709 1.10 0.86-1.40 35.7884 0.2530 1.16 0.90-1.50 19.2280
T 235(56) 348(54)
rs6937121 T 254(60) 423(65) 2.1263 0.1448 1.21 0.94-1.56 11.0048 0.1720 1.20 0.92-1.56 13.0720
G 166(40) 229(35)
rs6957 G 150(36) 241(37) 0.0802 0.7771 1.04 0.80-1.34 59.0596 0.6830 1.06 0.81-1.38 51.9080
A 268(64) 415(63)
rs1051730 C 403(97) 641(97) 0.2343 0.6284 1.20 0.57-2.52 47.3252 0.6480 1.17 0.60-2.29 49.2480
T 11(3) 21(3)
rs10947233 G 299(72) 526(79) 7.4524 0.0063 1.49 1.12-1.98 0.4788 0.0060 1.51 1.12-2.03 0.4560
T 115(28) 136(21)
rs11106030 C 355(85) 560(85) 0.0013 0.9716 1.01 0.71-1.42 73.8416 0.7030 1.07 0.75-1.52 53.4280
A 63(15) 100(15)
rs1130864 T 23(6) 43(7) 0.6081 0.4355 1.23 0.73-2.07 33.0980 0.3890 1.24 0.77-2.00 29.5640
C 389(94) 591(93)
rs1800629 G 379(90) 627(95) 7.8793 0.0050 1.94 1.21-3.10 0.3800 0.0060 1.97 1.21-3.21 0.4560
A 41(10) 35(5)
rs2241712 A 188(45) 342(52) 3.9820 0.0460 1.28 1.00-1.64 3.4960 0.0498 1.24 0.96-1.59 3.7848
G 226(55) 320(48)
rs2280090 G 395(94) 629(95) 0.9844 0.3211 1.30 0.77-2.20 24.4036 0.4640 1.22 0.72-2.06 35.2640
A 27(6) 33(5)
rs2395730 A 119(28) 209(32) 1.3886 0.2386 1.17 0.90-1.54 18.1336 0.0850 1.28 0.97-1.69 6.4600
C 303(72) 453(68)
rs2736118 A 397(94) 630(95) 0.6150 0.4329 1.24 0.72-2.12 32.9004 0.2850 1.36 0.78-2.37 21.6600
G 25(6) 32(5)
rs2736122 C 388(94) 632(95) 1.5783 0.2090 1.41 0.82-2.42 15.884 0.0510 1.77 1.02-3.07 3.8760
T 26(6) 30(5)
rs3817928 A 370(89) 596(90) 0.1202 0.7288 1.07 0.72-1.61 55.3888 0.4410 1.17 0.78-1.76 33.5160
G 44(11) 66(10)
rs584367 T 91(22) 152(23) 0.1399 0.7083 1.06 0.79-1.42 53.8308 0.8590 1.03 0.76-1.39 65.2840
C 323(78) 510(77)
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Table 3 Allele frequencies in COPD and control subjects for SNPs (Continued)
rs1042714 C 374(90) 607(92) 1.1947 0.2744 1.27 0.83-1.96 20.8544 0.1440 1.39 0.90-2.14 10.9440
G 40(10) 374(90)
rs13147758 A 283(69) 464(71) 0.8780 0.3487 1.14 0.87-1.49 26.5012 0.3840 1.13 0.86-1.49 29.1840
G 129(31) 186(29)
rs1422795 G 61(15) 108(16) 0.5395 0.4626 1.14 0.81-1.60 35.1576 0.8690 1.03 0.73-1.46 66.0440
A 353(85) 550(84)
rs1800796 C 293(71) 473(72) 0.1539 0.6948 1.06 0.80-1.39 52.8048 0.8250 1.03 0.78-1.36 62.7000
G 121(29) 185(28)
rs2236307 C 169(41) 286(43) 0.7270 0.3938 1.11 0.87-1.43 29.9288 0.4150 1.11 0.86-1.44 31.5400
T 245(59) 372(57)
rs2280091 A 383(93) 611(93) 0.1518 0.6968 1.10 0.68-1.77 52.9568 0.5020 1.17 0.74-1.87 38.1520
G 31(7) 45(7)
rs2853676 G 335(81) 544(83) 0.4538 0.5005 1.12 0.81-1.54 38.0380 0.2770 1.20 0.86-1.67 21.0520
A 77(19) 112(17)
rs868966 A 205(50) 337(51) 0.2934 0.5880 1.07 0.84-1.37 44.6880 0.7890 1.04 0.80-1.34 59.9640
G 209(50) 321(49)
Chi-square test and logistic analysis were used.
Logistic analysis was adjusted by potential confounders including age, gender, smoking history.
The p value with bold letters indicate those allele frequencies with significant differences between COPD and controls.
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(OR=3.30, 95% CI 1.47–7.44, p=0.0040).GG carriers
versus GT, TT carriers (OR=1.56, 95% CI 1.07–2.27,
p=0.0200).
The complete genotype distributions of the other
SNPs are listed in Table 5. Frequencies under different
genotypic models of each SNP were compared between
the COPD group and the control group.Table 4 Analysis of Genotypic Association of SNPs identified















* Logistic regression analysis was adjusted by potential confounders including age,Haplotype analysis
Using Haploview software, CRP gene polymorphisms were
determined to be in linkage disequilibrium (D’=1.0). Using
PHASE software, haplotype frequencies for the poly-
morphisms rs1205 and rs2808630 of CRP at chromosome
1 were compared with respect to frequency between
COPD patients and healthy controls. These two SNPs
formed three haplotypes: CC, CT, and TT (Table 6 andunder Genetic Models
Case (n,%) P value* OR* OR(95%CI) *
261(79) <0.0001 1.01 0.79-1.32
70(21)
213(65) 0.0240 1.55 1.06-2.26
115(35)
319(96) 0.0040 3.30 1.47-7.44
12(4)
207(63) 0.0200 1.56 1.07-2.27
124(37)
296(89) 0.0170 1.90 1.12-3.21
35(11)
238(73) 0.0040 1.82 1.21-2.73
89(27)
189(58) 0.0450 1.47 1.01-2.13
138(42)
gender, smoking history.
Table 5 Genotype frequencies of each SNP in COPD and control subjects for SNPs
SNP Allele Control (n,%) Case (n,%) Adjusted P value Adjusted OR Adjusted OR(95%CI) Adjusted P(Bonferroni)
rs1059823 GG 24(11) 39(11) 0.8120 0.93 0.52-1.67 61.7120
GA+AA 187(89) 292(89)
GG+GA 115(55) 183(55) 0.8760 0.97 0.68-1.39 66.5760
AA 96(45) 148(45)
rs17019336 AA 26(12) 35(11) 0.0100 0.14 0.09-0.22 0.7600
TA+TT 184(88) 294(89)
AA+AT 110(52) 207(63) 0.0210 1.54 1.07-2.21 1.5960
TT 100(48) 122(37)
rs1799964 TT 130(62) 206(63) 0.8010 0.95 0.66-1.38 60.8760
TC+CC 80(38) 121(37)
TT+TC 203(97) 313(96) 0.9180 0.96 0.41-2.23 69.7680
CC 7(3) 14(4)
rs1800610 TT 9(4) 13(4) 0.9940 1.00 0.41-2.44 75.5440
TC+CC 204(96) 318(96)
TT+TC 62(29) 99(30) 0.7350 1.07 0.72-1.59 55.8600
CC 151(71) 232(70)
rs2077464 TT 85(40) 138(43) 0.6620 1.09 0.75-1.57 50.3120
TC+CC 125(60) 181(57)
TT+TC 186(89) 282(88) 0.8190 0.94 0.53-1.64 62.2440
CC 24(11) 37(12)
rs2236302 CC+GC 208(99) 327(99) 0.8210 1.26 0.18-8.99 62.3960
GG 2(1) 2(1)
CC 161(77) 257(78) 0.4060 1.20 0.78-1.84 30.8560
GG+GC 49(23) 72(22)
rs2292566 AA 21(10) 36(11) 0.7410 1.11 0.61-2.0 56.3160
GG+AG 189(90) 293(89)
AA+AG 106(50) 156(47) 0.8610 1.03 0.72-1.48 65.4360
GG
rs2353397 CC 19(9) 121(37) 0.4850 1.24 0.68-2.28 36.8600
CT+TT 191(91) 210(63)
CC+CT 104(50) 261(79) 0.3740 1.18 0.82-1.69 28.4240
TT 106(50) 70(21)
rs25882 TT 30(14) 46(14) 0.9400 1.02 0.61-1.71 71.4400
CT+CC 180(86) 283(86)
TT+CT 117(56) 194(59) 0.3490 1.19 0.83-1.72 26.5240
CC 93(44) 135(41)
rs2808630 CC 4(2) 10(3) 0.4820 0.90 0.66-1.22 36.6320
CT+TT 206(98) 319(97)
CC+CT 62(30) 109(33) 0.2200 0.80 0.55-1.15 16.7200
TT 148(70) 220(67)
rs3749893 AA 100(47) 161(50) 0.4510 1.11 0.85-1.46 34.2760
AG+GG 113(53) 166(50)
AA+AG 186(87) 293(90) 0.6830 1.08 0.75-1.55 51.9080
GG 27(13) 34(10)
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Table 5 Genotype frequencies of each SNP in COPD and control subjects for SNPs (Continued)
rs4987835 AA 65(31) 121(38) 0.2280 1.27 0.86-1.86 17.3280
AG+GG 145(69) 196(62)
AA+AG 171(81) 261(80) 0.6900 1.10 0.69-1.76 52.4400
GG 39(19) 56(20)
rs709932 AA 8(4) 16(5) 0.7950 1.13 0.45-2.84 60.4200
AG+GG 202(96) 309(95)
AG+AA 65(31) 115(35) 0.2570 1.25 0.85-1.82 19.5320
GG 145(69) 210(65)
rs7217852 AA 86(41) 141(43) 0.6180 1.01 0.76-1.58 46.9680
AG+GG 124(59) 189(57)
AA+AG 187(89) 293(89) 0.7000 0.89 0.51-1.57 53.2000
GG 23(11) 37(11)
rs7776375 AA 83(39) 148(45) 0.0900 1.37 0.95-1.98 6.8400
AG+GG 130(61) 183(55)
AA+AG 187(39) 290(45) 0.7940 0.93 0.54-1.6 60.3440
GG 26(12) 41(12)
rs10069690 TT 12(6) 7(2) 0.7100 0.93 0.64-1.35 53.9600
CT+CC 194(94) 315(98)
TT+CT 69(33) 117(36) 0.0240 3.14 1.17-9.92 1.8240
CC 137(67) 205(64)
rs1051740 TT 72(35) 123(37) 0.5730 1.12 0.76-1.63 43.5480
TC+CC 133(65) 208(63)
TT+TC 175(85) 280(85) 0.6070 0.88 0.53-1.45 46.1320
CC 30(15) 51(15)
rs11155242 AA 169(82) 276(83) 0.3060 1.27 0.80-2.01 23.2560
AC+CC 38(18) 55(17)
AA+AC 203(98) 328(99) 0.5030 1.68 0.37-7.56 38.2280
CC 4(2) 3(1)
rs1295685 TT 19(9) 37(12) 0.4470 1.27 0.69-2.32 33.9720
TC+CC 188(91) 294(88)
TT+CT 99(48) 184(56) 0.1880 1.27 0.89-1.83 14.2880
CC 108(52) 147(44)
rs1435867 CC 5(2) 7(2) 0.7660 0.83 0.24-2.85 58.2160
CT+TT 200(98) 321(98)
CC+CT 50(24) 83(25) 0.5380 0.88 0.58-1.33 40.8880
TT 155(76) 245(75)
rs16909898 GG 2(1) 1(0.3) 0.4560 0.40 0.03-4.45 34.6560
GA+AA 204(99) 329(99.7)
GG+GA 31(15) 53(16) 0.3580 0.80 0.49-1.30 27.2080
AA 175(85) 277(84)
rs1881457 AA 117(56) 187(56) 0.9540 0.99 0.69-1.42 72.5040
AC+CC 91(44) 144(44)
AA+AC 191(92) 308(93) 0.7340 1.13 0.57-2.22 55.7840
CC 17(8) 23(7)
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Table 5 Genotype frequencies of each SNP in COPD and control subjects for SNPs (Continued)
rs2241718 TT 10(5) 26(8) 0.1380 1.80 0.83-3.88 10.4880
TC+CC 196(95) 305(92)
TT+TC 104(50) 180(54) 0.5480 1.12 0.78-1.60 41.6480
CC 102(50) 151(46)
rs2277027 CC 5(2) 10(3) 0.4990 1.47 0.49-4.44 37.9240
CA+AA 202(98) 321(97)
CC+CA 59(29) 96(29) 0.6170 0.90 0.61-1.34 46.8920
AA 148(71) 235(71)
rs2736100 TT 72(36) 108(34) 0.7840 0.95 0.65-1.39 59.5840
TG+GG 130(64) 207(66)
TT+TG 159(79) 260(83) 0.2490 1.32 0.83-2.10 18.9240
GG 43(21) 55(17)
rs35621 CC 114(56) 185(56) 0.3820 1.18 0.82-1.69 29.0320
CT+TT 91(44) 146(44)
CC+CT 191(93) 314(95) 0.5710 1.25 0.58-2.67 43.3960
TT 14(7) 17(5)
rs3995090 CC 98(48) 163(50) 0.2110 1.26 0.88-1.80 16.0360
CA+AA 107(52) 160(50)
CC+CA 190(93) 298(92) 0.6630 0.86 0.43-1.70 50.3880
AA 15(7) 25(8)
rs4246742 AA 71(35) 136(41) 0.0550 1.44 0.99-2.10 4.1800
AT+TT 134(65) 195(59)
AA+AT 173(84) 293(89) 0.1700 1.44 0.86-2.42 12.9200
TT 32(16) 38(11)
rs6712954 GG 128(62) 218(66) 0.1940 1.28 0.88-1.86 14.7440
GA+AA 78(38) 113(34)
GG+GA 193(94) 327(99) 0.0130 4.25 1.37-13.24 0.9880
AA 13(6) 4(1)
rs829259 AA 24(12) 35(11) 0.4770 0.81 0.45-1.46 36.2520
AT+TT 182(88) 296(89)
AA+AT 113(55) 198(60) 0.5920 1.11 0.77-1.59 44.9920
TT 93(45) 133(40)
rs10075508 TT 4(2) 6(2) 0.3660 0.49 0.10-2.30 27.8160
TC+CC 209(98) 320(98)
TT+TC 65(31) 102(31) 0.7280 1.07 0.73-1.58 55.3280
CC 148(69) 224(69)
rs10512249 TT 2(1) 1(0.3) 0.4560 0.40 0.04-4.45 34.6560
TC+CC 206(99) 310(99.7)
TT+TC 31(15) 51(16) 0.4150 1.27 0.71-2.27 31.5400
CC 177(85) 260(84)
rs12899618 GG 162(78) 259(79) 0.3010 1.26 0.82-1.94 22.8760
GA+AA 47(32) 66(21)
GG+GA 208(99) 320(98) 0.1430 0.20 0.02-1.71 10.8680
AA 1(1) 5(2)
rs13706 GG 85(40) 138(42) 0.7230 1.07 0.74-1.54 54.9480
GA+AA 125(60) 188(58)
GG+GA 187(89) 289(89) 0.3210 0.76 0.43-1.31 24.3960
AA 23(11) 37(11)
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Table 5 Genotype frequencies of each SNP in COPD and control subjects for SNPs (Continued)
rs1531697 AA 75(36) 134(41) 0.2920 1.22 0.84-1.77 22.1920
AT+TT 134(64) 191(59)
AA+AT 180(86) 277(85) 0.9290 0.98 0.58-1.645 70.6040
TT 29(14) 48(15)
rs1800925 TT 6(3) 12(4) 0.7160 1.22 0.43-3.47 54.4160
TC+CC 201(97) 294(96)
TT+TC 56(27) 93(31) 0.0790 1.41 0.96-2.08 6.0040
CC 151(73) 213(69)
rs3024791 GG 181(87) 293(90) 0.3770 1.27 0.75-2.14 28.6520
GA+AA 27(13) 31(10)
GG+GA 207(99.5) 323(99.7) 0.8760 1.25 0.08-20.07 66.5760
AA 1(0.5) 1(0.3)
rs6537302 AA 115(55) 194(62) 0.5150 1.13 0.79-1.62 39.1400
AT+TT 92(45) 117(38)
AA+AT 195(94) 286(92) 0.3070 0.68 0.33-1.41 23.3320
TT 12(6) 25(8)
rs6555465 GG 40(19) 83(26) 0.1920 1.34 0.86-2.10 14.5920
GA+AA 173(81) 241(74)
GG+GA 155(73) 227(70) 0.8710 0.97 0.65-1.45 66.1960
AA 58(27) 97(30)
rs673400 CC 0(0) 0(0) NA NA NA NA
CG+GG 208(100) 323(100)
CC+CG 178(86) 278(86) 0.8190 0.94 0.56-1.57 62.2440
GG 30(14) 45(14)
rs6889822 GG 84(40) 133(42) 0.4800 1.14 0.79-1.65 36.4800
GA+AA 124(60) 187(58)
GG+GA 184(88) 284(89) 0.7550 1.10 0.62-1.95 57.3800
AA 24(12) 36(11)
rs8004738 GG 45(22) 68(22) 0.7910 1.06 0.69-1.64 60.1160
GA+AA 163(78) 245(78)
GG+GA 139(67) 207(66) 0.6880 1.08 0.74-1.60 52.2880
AA 69(33) 106(34)
rs1003349 GG 68(33) 122(37) 0.1880 1.29 0.88-1.89 14.2880
GT+TT 140(67) 204(63)
GG+GT 170(82) 270(83) 0.6130 1.13 0.70-1.83 46.5880
TT 38(18) 56(17)
rs1032295 TT 119(56) 206(63) 0.1570 1.30 0.90-1.88 11.9320
TG+GG 94(44) 122(37)
TT+TG 201(94) 317(97) 0.2380 1.70 0.70-4.12 18.0880
GG 12(6) 11(3)
rs1042522 CC 37(18) 60(18) 0.8050 1.06 0.66-1.70 61.1800
GC+GG 173(82) 266(82)
CC+CG 147(70) 244(75) 0.2860 1.25 0.83-1.86 21.7360
GG 63(30) 82(25)
rs1052443 CC 96(46) 163(50) 0.2950 1.21 0.85-1.74 22.4200
CA+AA 114(54) 160(50)
CC+CA 185(88) 294(91) 0.1970 1.49 0.81-2.71 14.9720
AA 25(12) 29(9)
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Table 5 Genotype frequencies of each SNP in COPD and control subjects for SNPs (Continued)
rs12504628 TT 107(50) 166(50) 0.9000 0.98 0.68-1.40 68.4000
TC+CC 106(50) 162(50)
TT+TC 198(93) 309(94) 0.7810 1.11 0.54-2.27 59.3560
CC 15(7) 19(6)
rs1695 GG 5(2) 10(3) 0.4990 1.47 0.48-4.44 37.9240
GA+AA 204(98) 318(97)
GG+GA 67(32) 116(35) 0.5520 1.12 0.77-1.64 41.9520
AA 142(68) 212(65)
rs1800469 CC 39(19) 74(23) 0.9960 1.34 0.98-1.95 75.6960
TC+TT 169(81) 252(77)
CC+TC 143(69) 241(74) 0.2530 1.26 0.85-1.88 19.2280
TT 65(31) 85(26)
rs2853209 AA 42(20) 68(21) 0.4560 1.18 0.76-1.84 34.6560
AT+TT 169(80) 251(79)
AA+AT 149(71) 232(72) 0.4850 0.87 0.59-1.28 36.8600
TT 62(29) 92(28)
rs4073 AA 36(17) 68(21) 0.2460 1.32 0.83-2.09 18.6960
AT+TT 174(83) 256(79)
AA+AT 149(71) 232(72) 0.3260 1.22 0.82-1.83 24.7760
TT 61(29) 92(28)
rs6937121 TT 72(34) 141(43) 0.0280 1.52 1.05-2.20 2.1280
TG+GG 138(66) 185(57)
TT+TG 182(87) 282(86) 0.6680 0.89 0.53-1.50 50.7680
GG 28(13) 44(14)
rs6957 GG 21(10) 40(12) 0.2810 1.37 0.77-2.43 21.3560
GA+AA 188(90) 288(88)
GG+GA 129(62) 201(61) 0.8730 0.97 0.67-1.41 66.3480
AA 80(38) 127(39)
rs1051730 CC 196(95) 311(94) 0.5330 1.25 0.62-2.50 40.5080
CT+TT 11(5) 20(6)
CC+CT 207(100) 330(99.7) NA NA NA NA
TT 0(0) 1(0.3)
rs11106030 CC 153(73) 237(72) 0.9350 1.02 0.68-1.52 71.0600
CA+AA 56(27) 93(28)
CC+CA 202(96) 323(98) 0.3350 1.77 0.55-5.66 25.4600
AA 7(4) 7(2)
rs1130864 TT 0(0) 0(0) NA NA NA NA
TC+CC 206(100) 317(100)
TT+TC 23(11) 43(14) 0.3720 1.26 0.76-2.07 28.2720
CC 183(89) 274(86)
rs2241712 AA 44(21) 92(28) 0.1560 1.37 0.89-2.10 11.8560
AG+GG 163(79) 239(72)
AA+AG 144(69) 250(76) 0.2290 1.28 0.86-1.92 17.4040
GG 63(31) 81(24)
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Table 5 Genotype frequencies of each SNP in COPD and control subjects for SNPs (Continued)
rs2280090 GG 185(88) 299(90) 0.4650 1.23 0.71-2.14 35.3400
GA+AA 26(12) 32(10)
GG+GA 210(99.5) 330(99.4) 0.8760 1.25 0.08-20.07 66.5760
AA 1(0.5) 1(0.6)
rs2395730 AA 20(9) 48(15) 0.0490 1.77 1.00-3.13 3.7240
AC+CC 191(91) 283(85)
AA+AC 99(9) 161(49) 0.3610 1.18 0.82-1.70 27.4360
CC 112(53) 170(51)
rs2736118 AA 186(88) 299(90) 0.2740 1.38 0.78-2.45 20.8240
AG+GG 25(12) 32(10)
AA+AG 211(100) 331(100) NA NA NA NA
GG 0(0) 0(0)
rs2736122 CC 181(87) 301(90) 0.035 1.84 1.04-3.24 2.6600
CT+TT 26(13) 30(10)
CC+CT 181(100) 331(100) NA NA NA NA
TT 0(0) 0(0)
rs3817928 AA 166(81) 268(81) 0.4490 1.19 0.76-1.85 34.1240
AG+GG 41(19) 63(19)
AA+AG 204(99) 328(99) 0.7860 1.25 0.25-6.26 59.7360
GG 3(1) 3(1)
rs584367 TT 10(5) 14(4) 0.5010 0.73 0.30-1.82 38.0760
TC+CC 197(95) 317(96)
TT+TC 81(39) 138(42) 0.6410 1.10 0.76-1.57 48.7160
CC 126(61) 193(58)
rs1042714 CC 168(81) 280(85) 0.1020 1.48 0.93-2.36 7.7520
GC+GG 39(19) 49(15)
CC+GC 206(99) 327(99) 0.6990 0.62 0.06-6.90 53.1240
GG 1(1) 2(1)
rs13147758 AA 102(50) 168(52) 0.6310 1.09 0.76-1.57 47.9560
AG+GG 104(50) 157(48)
AA+AG 181(88) 296(91) 0.2920 1.38 0.76-2.49 22.1920
GG 25(12) 29(9)
rs1422795 GG 5(2) 11(3) 0.4990 1.47 0.48-4.44 37.9240
GA+AA 202(98) 313(97)
GG+GA 56(27) 97(29) 0.9400 0.99 0.66-1.46 71.4400
AA 151(73) 232(71)
rs1800796 CC 110(53) 168(51) 0.5080 0.89 0.62-1.27 38.6080
CG+GG 97(47) 161(49)
CC+CG 183(88) 305(97) 0.1060 1.68 0.90-3.16 8.0560
GG 24(12) 24(3)
rs2236307 CC 41(20) 62(19) 0.9460 0.98 0.62-1.55 71.8960
CT+TT 166(80) 267(81)
CC+CT 128(62) 224(68) 0.2150 1.27 0.87-1.86 16.3400
TT 79(38) 105(32)
rs2280091 AA 178(86) 283(86) 0.6730 1.11 0.68-1.82 51.1480
AG+GG 29(14) 45(14)
AA+AG 205(99) 328(100) NA NA NA NA
GG 2(1) 0(0)
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Table 5 Genotype frequencies of each SNP in COPD and control subjects for SNPs (Continued)
rs2853676 GG 137(67) 225(69) 0.3510 1.20 0.82-1.75 26.6760
GA+AA 69(33) 103(31)
GG+GA 198(97) 319(98) 0.3930 1.58 0.56-4.46 29.8680
AA 8(3) 9(2)
rs868966 AA 56(27) 84(26) 0.6620 0.91 0.60-1.38 50.3120
AG+GG 151(73) 245(74)
AA+AG 149(72) 253(77) 0.3970 1.20 0.79-1.80 30.1720
GG 58(28) 76(23)
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http://www.biomedcentral.com/1755-8794/5/64Figure 1). Among them, only the TT haplotype was more
frequently detected in controls (61%) compared with
COPD patients (52%) (OR=0.69, 95% CI 0.49–0.98,
p=0.0377). TGF-β1 rs2241718 and CDC97 rs6957 were in
linkage disequilibrium (D’=0.98); they formed two haplo-
types, GC and GT. These two haplotypes were respect-
ively more frequent in healthy controls compared with
COPD patients (OR=0.33, 95% CI 0.23–0.48, p=1.88×10-9)
(Table 6 and Figure 2). TGF-β1 rs1800469 and rs2241712
were also in linkage disequilibrium (D’=0.98); they formed
TG and CA haplotypes. However, no significant differ-
ences between the two groups were detected (Table 6 and
Figure 2).Discussion
In this study, we sought to determine which of 76 SNPs
we chose were associated with the development of COPD.
Our case–control study verified that the following SNPs
were associated with COPD: rs2353397 C, rs1800629 G,
rs2241712 A, rs1205 C, rs20541 T, rs2070600 G, andTable 6 Haplotypes of the CRP and TGF-β1 gene
SNPs(gene) Haplotype Control (n,%) Case
rs2241718(TGF-β1) GC 107(50) 83(25
rs6957(CDC97) Non-GC 106(50) 248(7
GT 107(50) 83(25
Non-GT 106(50) 248(7
rs1800469(TGF-β1) TG 111(52) 159(4
rs2241712(TGF-β1) Non-TG 102(48) 172(5
CA 94(44) 162(4
Non-CA 119(56) 169(5
rs1205(CRP) TT 130(61) 172(5





The p value with bold letters indicate those allele frequencies with significant differrs10947233 G. The rs2353397 C allele was most strongly
associated with COPD.
rs2353397 CC, CT genotypes of the HHIP gene were
associated with susceptibility to COPD in the Chinese
Han population. The HHIP gene is located at chromo-
some 4q31.21–31.3, position 145517578; it encodes the
HHIP protein [17]. This protein is a critical regulator of
the hedgehog (Hh) signalling pathway, which has been
implicated in cell development, cell repair, and cancer
development in multiple tissues [18]. The idea that
COPD could be associated with inappropriate growth or
structural defects in small airways makes HHIP an at-
tractive candidate developmental gene. Several GWASs
have also demonstrated that the 4q31 locus, which con-
tains the HHIP gene, is associated with COPD and lung
function [9-12]. A GWA meta-analysis for pulmonary
function in 20,890 participants of European white ancestry
revealed eight genes associated with COPD and concluded
that HHIP is associated with FEV1/FVC [10]. Few studies
prior to our current study have reported the SNPs of the
HHIP gene related to COPD in an Asian population.(n,%) χ2 P value OR OR(95%CI)
) 36.0947 1.88×10-9 0.33 0.23-0.48
5)
) 36.0947 1.88×10-9 0.33 0.23-0.48
5)
8) 0.8615 0.3533 0.85 0.60-1.20
2)
9) 1.2041 0.2725 1.21 0.86-1.71
1)
2) 4.3163 0.0377 0.69 0.49-0.98
8)
) 0.8883 0.3459 1.25 0.78-2.0
2)
) 1.6822 0.1946 1.30 0.87-1.92
1)
ences between COPD and controls.
Figure 2 Linkage disequilibrium of SNPs in the TGF-β1 and
CDC97 genes using Haploview software. The red color indicates
the higher linkage disequilibrium (D’=0.98) between the rs2241718
and rs6957; between the rs1800469 and rs2241712.
Figure 1 Linkage disequilibrium of SNPs in the CRP gene using
Haploview software. The red color indicates the higher linkage
disequilibrium (D’=1.0) between rs2808630 and rs1205.
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resulting in functional alteration and, subsequently, to
COPD. According to Zhou et al. (2012) [19], significant
decreases in expression of the HHIP gene at the mRNA
and protein levels were observed in COPD lungs com-
pared with lungs of smokers with normal lung function.
The risk-associated haplotype confers decreased activity
on the HHIP promoter, indicating that lower HHIP ex-
pression may exacerbate smoking-induced COPD patho-
genesis. Lemjabbar-Alaoui et al. (2006) [20] demonstrated
that hedgehog signaling proteins are critical mediators of
cigarette smoke-induced disease, such as lung cancer and
chronic airway inflammatory disease, and the expression
levels of hedgehog signaling proteins are modulated by
HHIP. Based on our current study of HHIP polymorph-
isms and the Hh signaling pathway, we need to further
our mechanistic research in the context of smoking.
Our results also demonstrated that rs1800629 GG car-
riers of the TNF-α gene were at several times the risk for
COPD compared with GA, AA carriers. TNF-α is criticalin the regulation of inflammation; it induces a cascade of
other inflammatory cytokines, chemokines, and other
growth factors; it is important in the pathogenesis of
many diseases. Several gene studies have also deter-
mined that the promoter polymorphism of TNF-α is
associated with chronic bronchitis or the extent of
emphysematous changes. Two of these studies were per-
formed with Caucasian subjects, two with Japanese sub-
jects [21-24]. The promoter polymorphism may have
caused varied concentrations of serum TNF-α, which
have been associated with induced sputum in bronchial
biopsies and with bronchoalveolar lavage fluid in stable
COPD patients and during exacerbations, compared
with that of control subjects [25]. Some investigators
have shown that TNF-α genotypes do influence the se-
verity of infectious diseases, while others have concluded
that polymorphisms of this gene promoter are of no
functional consequence [26,27].
A polymorphism of the TGF-β1 gene, rs2241712 A,
tended to be a risk-associated allele in our study. TGF-
β1 is one of the important cytokines involved in the in-
flammatory process of COPD. TGF-β1 expression is
usually increased in the airways of patients. Su et al.
(2005) [28] found that more carriers of the -800A allele,
Guo et al. BMC Medical Genomics 2012, 5:64 Page 17 of 19
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among the COPD patients, but only 84 COPD cases and
97 healthy controls participated in their research. In
addition, we used a Chinese Han population, while Su
et al. recruited people in a general Chinese population.
Van Diemen et al. (2010) [29] showed that the TGF-β1
rs6957 SNP haplotype with the major allele of rs6957
and minor alleles of rs1800469 and rs1982073 were
associated with COPD. The differences in study popula-
tions may explain these dissimilarities between our stud-
ies. Various studies have indicated that certain SNPs of
the TGF-β1 gene are functional and result in higher
levels of circulating TGF-β1 [30,31].
The SNP rs20541 at IL-13 gene exon 4 tended to be
associated with COPD in our study. Genotype TT, CT
carriers were at risk. IL-13 is a Th2 cytokine implicated
in the recruitment of inflammatory cells from the blood
to the lung, which may be involved in the pathogenesis
of COPD. In experimental studies, the overexpression of
IL-13 in the adult murine lung caused emphysema [32].
The number of IL-13+ cells was elevated in the bron-
chial submucosa of smokers with chronic bronchitis
compared to asymptomatic smokers [33]. rs2066960,
rs20541, and rs1295685 in the IL-13 gene were asso-
ciated with COPD risk and lower baseline lung function
in the study by Beghé et al. (2010) [34], which used a
Caucasian study population. We chose the same SNPs
located in the IL-13 gene, but our results showed that
only rs20541 is of significance in susceptibility to COPD
in the Chinese Han population. In addition, another
study revealed the role of rs20541 in another chronic
airway inflammatory disease (asthma), which indicates
that the polymorphism in the coding region might con-
tribute to airflow limitation [35].
The polymorphism of another inflammatory marker in
the CRP gene, rs1205 C, was also a risk-associated allele
according to our current study. Sunyer et al. (2008) [36]
assessed the association between rs1205 and lung function;
they demonstrated that the TT homozygous genotype in
the CRP gene is associated with better lung function. Our
result that the TT genotype protects people against COPD
is similar to theirs because COPD is characterized by air-
flow limitation according to lung function. This polymorph-
ism has been previously reported associated with varied
levels of CRP in several studies [37]. Higher levels of CRP
in peripheral blood may cause impaired lung function [38].
Two other SNPs, AGER rs2070600 and PPT2 rs10947233,
tended to be associated with COPD in our current
study. rs2070600 GG and rs10947233 GG, GT carriers
tended to develop COPD. An occidental GWAS demon-
strated a role for the chromosome 6p21 locus including
the AGER and PPT2 genes in COPD development in smo-
kers [39]. Repapi et al. (2010) [12] reported a meta-
analysis of GWAS results from 20,288 participants andfollow-up analyses in 54,276 participants; they identified
five novel, genome-wide, significant loci for pulmonary
function containing AGER rs2070600, but their analysis
subject group did not include Asians. In addition,
rs2070600 was associated with severe COPD in a study of
Caucasian smokers from Poland [40]. The two SNPs of
AGER and PPT2 were also identified associated with
FEV1/FVC in the 2009 work of Hancock et al. [10].
In addition, our study revealed some haplotypes com-
posed of rs1205 and rs 2808630 in the CRP gene,
rs2241718 and rs 6957 at the TGF-β1 and CDC97 genes.
In our future research, we will further analyze our data
with regard to lung function.
Our research had some limitations. First, a larger sam-
ple size would have improved quality of the results. Sec-
ond, although we selected 97 SNPs for the study and
found some loci related to the disease, further GWASs
of COPD are needed in the Chinese Han population to
identify more associated polymorphisms. It is likely that
more genetic risk factors than those identified in this
study contribute to the development of COPD. In our
future work, we will further our investigation on gene
function of the genetic factors related to the develop-
ment of COPD.
Conclusion
Our findings identified some genetic variants associated
with COPD. This study has provided important informa-
tion regarding the association of these polymorphisms to
the susceptibility to COPD in the Chinese Han popula-
tion. However, these findings need to be verified. These
data emphasize the need for further research regarding
gene function in COPD that will ultimately contribute to
future gene therapies for this significant and costly dis-
ease in the Chinese Han population.
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